Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $184.41 | 3 | 72.5% |
| Education | $38.86 | 3 | 15.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31.25 | 1 | 12.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $98.33 | 1 | $0 (2017) |
| Seattle Genetics, Inc. | $56.93 | 2 | $0 (2018) |
| PFIZER INC. | $45.90 | 2 | $0 (2018) |
| Janssen Scientific Affairs, LLC | $41.44 | 1 | $0 (2022) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $41.44 | 1 | Janssen Scientific Affairs, LLC ($41.44) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2018 | $58.19 | 3 | PFIZER INC. ($45.90) |
| 2017 | $142.97 | 2 | Amgen Inc. ($98.33) |
All Payment Transactions
7 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/28/2022 | Janssen Scientific Affairs, LLC | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $41.44 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 10/11/2018 | PFIZER INC. | BAVENCIO (Drug) | Education | In-kind items and services | $14.65 | General |
| Category: ONCOLOGY | ||||||
| 08/09/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 06/30/2018 | PFIZER INC. | BOSULIF (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $31.25 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 07/08/2017 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $44.64 | General |
| Category: Not Applicable | ||||||
| 06/26/2017 | Amgen Inc. | Kyprolis (Biological) | Food and Beverage | In-kind items and services | $98.33 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 133 | 163 | $57,951 | $11,133 |
| 2022 | 3 | 55 | 57 | $7,720 | $3,456 |
| 2021 | 35 | 1,525 | 56,532 | $2.5M | $588,347 |
| 2020 | 56 | 3,100 | 124,980 | $5.9M | $1.2M |
All Medicare Procedures & Services
100 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 56 | 80 | $26,880 | $4,026 | 15.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 24 | 24 | $14,760 | $2,320 | 15.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 17 | 20 | $3,275 | $1,993 | 60.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 22 | 24 | $11,352 | $1,851 | 16.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 14 | 15 | $1,684 | $943.02 | 56.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 14 | 14 | $2,780 | $1,417 | 51.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 15 | 16 | $2,194 | $1,148 | 52.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 13 | 14 | $1,537 | $742.28 | 48.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 13 | 13 | $1,209 | $148.85 | 12.3% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2021 | 13 | 9,600 | $1.3M | $392,074 | 30.5% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2021 | 25 | 21,700 | $455,700 | $59,033 | 13.0% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 47 | 187 | $29,920 | $29,920 | 100.0% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 53 | 179 | $122,794 | $20,414 | 16.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 151 | 243 | $43,874 | $15,406 | 35.1% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2021 | 17 | 12,750 | $51,000 | $11,360 | 22.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 56 | 92 | $27,769 | $8,555 | 30.8% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2021 | 12 | 6,760 | $54,080 | $8,374 | 15.5% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2021 | 45 | 247 | $37,544 | $6,155 | 16.4% |
| 96417 | Infusion of different chemotherapy drug or substance into a vein up to 1 hour | Office | 2021 | 25 | 69 | $23,046 | $3,960 | 17.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 164 | 506 | $17,710 | $3,932 | 22.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2021 | 121 | 327 | $20,274 | $3,377 | 16.7% |
| 96401 | Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | Office | 2021 | 13 | 44 | $9,020 | $2,817 | 31.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 16 | 18 | $6,815 | $2,473 | 36.3% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2021 | 32 | 1,010 | $123,220 | $2,424 | 2.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 28 | 42 | $12,768 | $2,296 | 18.0% |
About Dr. Dean Mcgaughey, MD
Dr. Dean Mcgaughey, MD is a Hematology & Oncology healthcare provider based in Norfolk, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/17/2005. The National Provider Identifier (NPI) number assigned to this provider is 1063417764.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dean Mcgaughey, MD has received a total of $254.52 in payments from pharmaceutical and medical device companies, with $41.44 received in 2022. These payments were reported across 7 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($184.41).
As a Medicare-enrolled provider, Mcgaughey has provided services to 4,813 Medicare beneficiaries, totaling 181,732 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 100 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Medical Oncology
- Location Norfolk, VA
- Active Since 06/17/2005
- Last Updated 09/18/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1063417764
Products in Payments
- Kyprolis (Biological) $98.33
- ADCETRIS (Biological) $56.93
- DARZALEX (Biological) $41.44
- BOSULIF (Drug) $31.25
- BAVENCIO (Drug) $14.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Norfolk
Rabih Fahed, M.d, M.D
Hematology & Oncology — Payments: $337,010
Gary Simmons, Do, DO
Hematology & Oncology — Payments: $66,315
Michael Danso, M.d, M.D
Hematology & Oncology — Payments: $54,407
Dr. Shanley Banaag, D.o, D.O
Hematology & Oncology — Payments: $3,419
Thomas Alberico, Md, MD
Hematology & Oncology — Payments: $572.79
Dr. Ranjit Goudar, M.d, M.D
Hematology & Oncology — Payments: $549.21